DexCom Reports Q4 2025 Revenue of $1.26 Billion, Up 13%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Source: NASDAQ.COM
- Revenue Growth: DexCom's preliminary Q4 2025 total revenue reached approximately $1.26 billion, reflecting a 13% year-over-year increase and surpassing the Zacks consensus estimate of $1.25 billion, indicating strong market performance.
- U.S. and International Performance: U.S. revenues were about $892 million, an 11% increase year-over-year, while international revenues rose 18% to around $368 million, demonstrating the effectiveness of the company's global expansion strategy.
- Gross and Operating Margins: The company estimates an adjusted gross profit margin of approximately 61% and an operating margin of 20-21% for 2025, with elevated manufacturing scrap rates impacting margins, yet operational leverage has helped achieve overall margin expansion.
- 2026 Outlook: DexCom projects total revenues for 2026 to be between $5.16 billion and $5.25 billion, representing an estimated growth of 11-13%, with expected gross margins improving to 63-64%, reflecting strong confidence in future growth and robust market demand.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 84.81 USD with a low forecast of 68.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
23 Analyst Rating
19 Buy
3 Hold
1 Sell
Strong Buy
Current: 73.360
Low
68.00
Averages
84.81
High
112.00
Current: 73.360
Low
68.00
Averages
84.81
High
112.00
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three Previous Stock Selections Subtly Indicate Buy Opportunities Once More
- Market Opportunities: Investors may find renewed opportunities in previously recommended stocks from healthcare, oil services, and consumer staples sectors.
- Signs of Momentum: These stocks are showing signs of renewed momentum, suggesting potential upside for investors.
- Sector Rotation: The leadership in these sectors has already rotated, indicating a shift in market dynamics.
- Investor Consideration: Investors are encouraged to take a fresh look at these stocks as they may present attractive investment options.
Continue Reading
Kaskela Law Investigates Potential Fiduciary Breach at DexCom
- Investigation Launched: Kaskela Law LLC is investigating potential breach of fiduciary duty claims against DexCom, Inc. (NASDAQ:DXCM) to protect the interests of long-term investors and ensure transparency and compliance in corporate governance.
- Securities Fraud Complaint: A securities fraud complaint filed against DexCom alleges that during the period from April 28, 2023, to July 25, 2024, senior executives made a series of materially false statements, potentially causing significant investor losses.
- Earnings Guidance Cut Impact: On July 25, 2024, DexCom shocked the market by slashing its full-year revenue guidance by $300 million, primarily due to severe underperformance in the Type 2 basal market, leading to a more than 40% drop in stock price to $64.00 per share the following day.
- Shareholder Rights Protection: Kaskela Law encourages current DexCom shareholders who have owned shares since at least April 28, 2023, to contact their attorneys to protect their rights in potential legal actions and ensure accountability from the company's executives.
Continue Reading